The US regulator reportedly will move to a single-trial default for most drug and biologic approvals, marking the agency’s ...

Chinese biotech TransThera has reported new Phase II data showing its experimental kinase inhibitor tinengotinib delivered ...

Shares of US drug developer Denali Therapeutics closed up 5.8% at $20.11 yesterday, after it announced a $275 million ...

The basal cell carcinoma market is expected to expand over the next decade as rising diagnoses, aging populations and ...

A Melbourne-based biotech company developing immune-based approaches for Alzheimer’s disease, using extracellular vesicles ...

Ireland incorporated Cosmo Pharmaceuticals saw its shares rise more than 3% to $91.80 yesterday, after it announced ...

US biotech Vanda Pharmaceuticals (Nasdaq: VNDA) has announced that the American medicines regulator removed a partial ...

The US Food and Drug Administration has approved Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19 ...

A Netherlands-linked biotech company developing targeted protein degraders designed to remove disease-relevant membrane ...

US oncology specialist Crescent Biopharma has announced an exclusive partnership with China’s Sichuan Kelun-Biotech ...

Accession Therapeutics, a UK clinical-stage biopharmaceutical company developing next generation cancer immunotherapies, ...

The UK’s BioIndustry Association (BIA) today released its report, From innovation to impact: unlocking patient access to ...